Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab with HDT/ASCT in Multiple Myeloma
NCT02716805Phase 1Terminated
- Sponsor
- Ludwig Cancer Research
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab and durvalumab in multiple myeloma (MM) (4 cohorts), sponsored by Ludwig Cancer Research. Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events up to 14 months. Started Dec 2016; status: terminated.
02
Drugs
tremelimumabdurvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02716805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716805.